Acutus Is Trying To Fundamentally Change Understanding Of Arrhythmia With AcQMap
Executive Summary
New trial results show Acutus Medical's AcQMap platform has the ability to classify conduction patterns and localized non-pulmonary-vein therapeutic targets for ablation to treat atrial fibrillation, which could have implications for both treatment of atrial fibrillation and understanding the genetic markers for this common arrhythmia, according to the authors.
You may also be interested in...
Medtronic, Farapulse Advance Pulsed Field Ablation With US Trials
Two pivotal US trials of pulsed field ablation systems began in early March. Farapulse is sponsoring the ADVENT randomized trial of the Farapulse PFA system and Medtronic launched the international PULSED AF trial of its PulseSelect PFA system.
Exec Chat: Steven Mickelsen Helps Acutus Translate Science Into Improved Outcomes
Mickelsen, an electrophysiologist at the University of Iowa, recently joined the rapidly growing San Diego-area company as Chief Translational Science Officer and is helping to guide the company’s development of novel electrophysiology therapies to treat cardiac arrhythmias.
J&J, Acutus And Boston Scientific Announce Plans For Pulsed Field AF-Ablation Technologies
Pulsed field ablation, which uses a controlled electrical field instead of focused heat or cold, has shown promise as a safer alternative to thermal and cryo approaches for atrial fibrillation ablation.